SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

US FDA accepts Glenmark’s application for pain killer drug

01 Apr 2010 Evaluate

Drug firm Glenmark on Wednesday said US Food and Drug Administration (FDA) has accepted its new drug application for pain killer oxycodone hydrochloride capsules. FDA in a letter to the company indicated it has completed the filing review and has begun reviewing the application for oxycodone hydrochloride.

 

The company had filed the new drug application (NDA) for oxycodone hydrochloride capsules in order to make it eligible for continued sales in the US to meet the criteria set by the health regulator, which requires old drugs to be approved by it. The US FDA had started a new policy in June 2006, for transitioning of grandfathered products that were manufactured and sold in the US prior to its existence, to approved products.

 

Pursuant to the Prescription Drug User Fee Act (PDUFA) guidelines, once a new drug application is accepted for filing, it is expected that the FDA will complete review and provide an action letter with respect to the NDA within 10 months following its submission.

 

Glenmark Generics Ltd, a subsidiary of Glenmark Pharmaceuticals, submitted the NDA for oxycodone hydrochloride drug both in capsule and liquid solutions form in association with its partner LVT. The pain killer drug has reported total sales of $16 million in the twelve-month period ending December 2009.

crackcrack

Glenmark Pharma Share Price

2247.90 -1.65 (-0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×